Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
Authors
Keywords
-
Journal
BMC CANCER
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-30
DOI
10.1186/s12885-020-07077-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia
- (2019) Renato Bassan et al. HAEMATOLOGICA
- Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
- (2019) Stefano Molica et al. Clinical Lymphoma Myeloma & Leukemia
- ClonoSEQ assay for the detection of lymphoid malignancies
- (2019) Anna Monter et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies
- (2019) Ricardo Sánchez et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Pipeline Repertoire for Ig-Seq Analysis
- (2019) Laura López-Santibáñez-Jácome et al. Frontiers in Immunology
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- (2018) Michael Hallek et al. BLOOD
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when
- (2018) Jo Caers et al. HAEMATOLOGICA
- New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies
- (2018) Irene Dogliotti et al. Journal of Clinical Medicine
- Minimal residual disease analysis in myeloma – when, why and where
- (2017) Uday Yanamandra et al. LEUKEMIA & LYMPHOMA
- Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia
- (2017) Donald A. Berry et al. JAMA Oncology
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
- (2017) Nikhil C. Munshi et al. JAMA Oncology
- Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2016) D. Hoelzer et al. ANNALS OF ONCOLOGY
- Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation
- (2016) Gabriel N. Mannis et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) B. Eichhorst et al. ANNALS OF ONCOLOGY
- Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
- (2015) J. J. M. van Dongen et al. BLOOD
- Reconstructing and mining the B cell repertoire with ImmunediveRsity
- (2015) Bernardo Cortina-Ceballos et al. mAbs
- Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival
- (2014) Aaron C. Logan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH
- (2014) D. Wu et al. CLINICAL CANCER RESEARCH
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
- (2013) Andy C. Rawstron et al. JOURNAL OF CLINICAL ONCOLOGY
- Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
- (2012) M. Faham et al. BLOOD
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
- (2008) B. Paiva et al. BLOOD
- Error models for immunoassays
- (2008) W. A Sadler ANNALS OF CLINICAL BIOCHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started